Watch our capabilities presentation to learn how our integrated CDMO solutions accelerate immune cell therapy development from early-phase to commercial readiness.
May 15, 2025 – Research Triangle Park, NC – Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring...
Assay development is essential to cell therapy success—ensuring consistency, precision, and product effectiveness. But for complex cell-based assays, early-phase innovators often face high costs and...
DownloadYou have time, money, and expertise invested in your cell therapy program—let us help you bring it to market. Learn how Kincell is well-positioned to...
DownloadMay 15, 2025 – Research Triangle Park, NC – Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring...
Read MoreWatch our capabilities presentation to learn how our integrated CDMO solutions accelerate immune cell therapy development from early-phase to commercial readiness.
Preferred Partner Network (PPN) members will become Centers of Excellence for the IRO® platform combining best-in-class technology with industry-leading development and manufacturing capabilities. PHILADELPHIA and...
Read MoreMarch 17, 2025 (Research Triangle Park, NC): Kincell Bio, a leader in cell therapy development and manufacturing, is excited to announce the appointment of Larry...
Read More
1622 NW 55th Place
Gainesville, FL 32653
20 TW Alexander Dr, Suite 130
RTP, NC 27703
